This content is restricted.
Brief
"On March 7, 2025, the Therapeutic Goods Administration (TGA) issued an update regarding Potential risk of neurodevelopmental disorders in children born to men taking sodium valproate. A retrospective observational study suggested an increased risk of neurodevelopmental disorders in children born to men treated with sodium valproate compared to those treated with lamotrigine or levetiracetam, prompting new warnings and precautions for health professionals and male patients."
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested